Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Blinded, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of One Dose of the SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in People Aged 18 Years and Older Who Had Received Two or Three Doses of Inactivated COVID-19 Vaccine

NCT05745545 is registered in ClinicalTrials.gov with AIM Vaccine Co., Ltd. as lead sponsor.

NCT NCT05745545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05745545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Blinded, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of One Dose of the SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in People Aged 18 Years and Older Who Had Received Two or Three Doses of Inactivated COVID-19 Vaccine
Lead sponsor
AIM Vaccine Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
January 4, 2023
Completion date
November 30, 2023
Enrollment
3,200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2